Electronic Supplementary Material (ESI) for Metallomics. This journal is © The Royal Society of Chemistry 2019

## **Supplementary Tables**

**Title**: "Pyrazolopyrimidinones, a novel class of copper-dependent bactericidal antibiotics against multi-drug resistant *S. aureus*"

**Authors**: Cameron L. Crawford<sup>1</sup>, Alex G. Dalecki<sup>1</sup>, Whitney T. Narmore<sup>1</sup>, Jessica Hoff<sup>1</sup>, Audra A. Hargett<sup>2</sup>, Matthew B. Renfrow<sup>2</sup>, Man Zhang<sup>3</sup>, Madumali Kalubowilage<sup>3</sup>, Stefan H. Bossmann<sup>3</sup>, Stacy L. Queern<sup>4,5</sup>, Suzanne E. Lapi<sup>4,5</sup>, Robert N. Hunter III<sup>6</sup>, Donghui Bao<sup>6</sup>, Corinne E. Augelli-Szafran<sup>6</sup>, Olaf Kutsch<sup>1</sup>, and Frank Wolschendorf<sup>1,#</sup>

<sup>&</sup>lt;sup>1</sup>Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA <sup>2</sup>Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA

<sup>&</sup>lt;sup>3</sup> Department of Chemistry, Kansas State University, Manhattan, KS, USA

<sup>&</sup>lt;sup>4</sup> Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA

<sup>&</sup>lt;sup>5</sup> Department of Chemistry, Washington University in St. Louis

<sup>&</sup>lt;sup>6</sup> Department of Chemistry, Drug Discovery Division, Southern Research, Birmingham, AL, USA

## Table S1: Antibiotic resistance profile of MRSA strains.

All MRSA strains were tested for antibiotic resistance by UAB Laboratory Medicine. R= resistant and S = sensitive. Amox/Cla = Amoxicillin, Amp/Sul = Ampicillin/sulbactam, Cetri = Ceftriaxone, Cipro = Ciprofloxacin, Clinda = Clindamycin, Dapto = Daptomycin, Eryth = Erythromycin, Gent = Gentamicin, Levo = Levofloxacin, Linez = Linezolid, Ox = Oxacillin, Pen = Penicillin, Quin/Dalf = Quinupristin/dalfopristin, Rif = Rifampicin, SXT = Sulfamethaxole/Trimethoprim, Tetra = Tetracycline, and Vanc = Vancomycin.

| ABX       | MRSA-1 | MRSA-2 | MRSA-3 | MRSA-4 | MRSA-5 |
|-----------|--------|--------|--------|--------|--------|
| Amox/Cla  | R      | R      | R      | R      | R      |
| Amp/Sul   | R      | R      | R      | R      | R      |
| Cetri     | R      | R      | R      | R      | R      |
| Cipro     | S      | R      | S      | S      | R      |
| Clinda    | R      | R      | S      | S      | R      |
| Dapto     | S      | S      | S      | S      | S      |
| Eryth     | R      | R      | R      | R      | R      |
| Gent      | S      | S      | S      | S      | S      |
| Levo      | S      | R      | S      | S      | R      |
| Linez     | S      | S      | S      | S      | S      |
| Ox        | R      | R      | R      | R      | R      |
| Pen       | R      | R      | R      | R      | R      |
| Quin/Dalf | S      | S      | S      | S      | S      |
| SXT       | S      | S      | S      | S      | S      |
| Tetra     | R      | S      | S      | S      | S      |
| Vanc      | S      | S      | S      | S      | S      |

## Table S2: Drug-like properties of PZPs.

MW: molecular weight in g/mol; cLogP:  $log_{10}$  of Octanol:water partition coefficient; LogSW:  $log_{10}$  of intrinsic water solubility; RB: rotatable bonds; tPSA: topological polar surface area; hDon: proton donating atoms; hAcc: proton accepting atoms. All values were provided by the supplier (<a href="https://www.hit2lead.com">www.hit2lead.com</a>).

| PZP | Structure | MW    | Mol. Formula | cLogP | LogSW  | RB | tPSA  | hDon | hAcc |
|-----|-----------|-------|--------------|-------|--------|----|-------|------|------|
| 915 |           | 349.8 | C20H16CIN3O  | 3.85  | -5.039 | 3  | 50.16 | 1    | 3    |
| 716 |           | 365.4 | C24H19N3O    | 4.31  | -5.545 | 3  | 50.16 | 1    | 3    |
| 720 | ns hand   | 301.8 | C16H16CIN3O  | 3.34  | -4.253 | 1  | 50.16 | 1    | 3    |
| 894 |           | 285.7 | C15H12CIN3O  | 2.82  | -3.692 | 1  | 50.16 | 1    | 3    |
| 832 |           | 294.1 | C13H9Cl2N3O  | 3.04  | -3.942 | 1  | 50.16 | 1    | 3    |
| 284 |           | 253.3 | C15H15N3O    | 2.65  | -3.311 | 1  | 50.16 | 1    | 3    |
| 643 |           | 273.7 | C14H12CIN3O  | 2.28  | -3.144 | 1  | 50.16 | 1    | 3    |

**Table S3: ADME properties of PZP 915.** Half-life of 1  $\mu$ M 915 or 1  $\mu$ M 915 + 0.5  $\mu$ M Cu was assessed in human liver microsomes. Solubility of 915 was determined in ddH<sub>2</sub>O. Distribution coefficient (LogD) was determined experimentally.

| ID     | Half-life (min) | Solubility (µM) | Sol RSD% | LogD  |
|--------|-----------------|-----------------|----------|-------|
| 915    | 55.9            | 38              | 1.9      | >3.70 |
| 915+Cu | 52.6            | 44.4            | 6.4      | >3.53 |

Table S4: Binding constants for  $M(PZP 915)_3^{2+}$  complexes. Counter anions: a) bromide, b) sulfate, c) chloride

| 915 metal complexes          | Binding constant                        | Units                            |
|------------------------------|---|----------------------------------|
| Cu(PZP915)3 <sup>2+ a)</sup> | $1.12 \times 10^8 \pm 0.02 \times 10^8$ | L <sup>3</sup> mol <sup>-3</sup> |
| Zn(PZP915)3 <sup>2+b)</sup>  | $6.6 \times 10^8 \pm 0.3 \times 10^8$   | L <sup>3</sup> mol <sup>-3</sup> |
| Fe(PZP915)3 <sup>2+c)</sup>  | $5.3 \times 10^8 \pm 0.3 \times 10^8$   | L <sup>3</sup> mol <sup>-3</sup> |
| Cu(PZP915)2 <sup>+ a)</sup>  | $2.35 \times 10^6 \pm 0.9 \times 10^5$  | L <sup>2</sup> mol <sup>-2</sup> |
| Cu(PZP915) <sup>+ a)</sup>   | $3.80 \times 10^5 \pm 0.4 \times 10^4$  | L mol <sup>-1</sup>              |

**Table S5: Binding constants for the individual binding reactions.** Binding constants were calculated based on the assumption of a stepwise addition of ligands.

| 915 Binding Reactions                | Binding<br>Constants | Units              |
|--------------------------------------|----------------------|--------------------|
| K1 = Cu+PZP915                       | $3.80 \times 10^5$   | Lmol <sup>-1</sup> |
| K2 = Cu(PZP915)+PZP915               | 6.18                 | Lmol <sup>-1</sup> |
| K3 = Cu(PZP915) <sub>2</sub> +PZP915 | 47.65                | Lmol⁻¹             |